Oblimersen combined with docetaxel, adriamycin and cyclophosphamide as neo-adjuvant systemic treatment in primary breast cancer: final results of a multicentric phase I study.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Annals of Oncology

• Publication date

  2008-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/annonc/mdn280PMID 18477581
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Randomized Phase III Trial of Fludarabine Plus Cyclophosphamide With or Without Oblimersen Sodium (Bcl-2 antisense) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

  2008cited by this paper
• A Matter of Life and Death

  2008cited by this paper
• Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.

  2007cited by this paper
• A Phase II study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse.

  2006cited by this paper
• Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group.

  2006cited by this paper
• A phase I, pharmacokinetic and biologic correlative study of oblimersen sodium (Genasense, G3139) and irinotecan in patients with metastatic colorectal cancer.

  2006cited by this paper
• Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia.

  2005cited by this paper
• Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.

  2005cited by this paper
• Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity.

  2005cited by this paper
• Early results of a phase I trial of oblimersen sodium for relapsed or refractory Waldenstrom's macroglobulinemia.

  2005cited by this paper
• In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study.

  2005cited by this paper
• A Phase II, Pharmacokinetic, and Biological Correlative Study of Oblimersen Sodium and Docetaxel in Patients with Hormone-Refractory Prostate Cancer

  2005cited by this paper
• Oblimersen Sodium (Genasense bcl-2 Antisense Oligonucleotide)

  2004cited by this paper
• A Phase I Pharmacokinetic and Biological Correlative Study of Oblimersen Sodium (Genasense, G3139), an Antisense Oligonucleotide to the Bcl-2 mRNA, and of Docetaxel in Patients with Hormone-Refractory Prostate Cancer

  2004cited by this paper
• Induction of apoptosis and chemosensitization of mesothelioma cells by Bcl‐2 and Bcl‐xL antisense treatment

  2003cited by this paper
• Proapoptotische Therapie mit Oblimersen (bcl-2-Antisense-Oligonukleotid) – Übersicht über präklinische und klinische Daten

  2003cited by this paper
• [Proapoptotic therapy with oblimersen (bcl-2 antisense oligonucleotide)--review of preclinical and clinical results].

  2003influential reference
• Oblimersen sodium (G3139 Bcl-2 antisense oligonucleotide) therapy in Waldenstrom's macroglobulinemia: a targeted approach to enhance apoptosis.

  2003cited by this paper
• International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations.

  2003cited by this paper
• Apoptosis-targeted therapies for cancer.

  2003cited by this paper
• A matter of life and death.

  2002cited by this paper
• Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer.

  2002cited by this paper
• Oblimersen Bcl-2 Antisense: Facilitating Apoptosis in Anticancer Treatment

  2002cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors

  2000cited by this paper
• Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma.

  2000cited by this paper
• Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides.

  2000cited by this paper
• Genetic analysis of chemoresistance in primary murine lymphomas

  2000cited by this paper
• Antisense bcl-2 treatment increases programmed cell death in non-small cell lung cancer cell lines.

  1999cited by this paper
• Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell lines.

  1998cited by this paper
• BCL-2 family: regulators of cell death.

  1998cited by this paper
• Analysis of Bax and Bcl-2 expression in p53-immunopositive breast cancers.

  1997cited by this paper
• Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence.

  1997cited by this paper
• Analysis of Bax and Bcl-2 expression in p53-immunopositive breast cancers.

  1997influential reference
• Combination adriamycin and suramin induces apoptosis in bcl-2 expressing prostate carcinoma cells.

  1995cited by this paper
• [Histologic regression of breast cancer after primary (neoadjuvant) chemotherapy].

  1994cited by this paper
• Reversal of Chemoresistance of Lymphoma Cells by Antisense-Mediated Reduction of bcl-2 Gene Expression

  1994cited by this paper
• Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model.

  1994cited by this paper
• Histologische Regression des Mammakarzinoms nach primärer (neoadjuvanter) Chemotherapie

  1994cited by this paper
• [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue].

  1987cited by this paper

• Research progress on non-protein-targeted drugs for cancer therapy

  2023cites this paper
• Targeting Bcl-2 for cancer therapy.

  2021cites this paper
• Chemical Synthesis and Biological Application of Modified Oligonucleotides.

  2020cites this paper
• Efficacy of DMBG and gemcitabine as a combination treatment on advanced pancreatic cancer, and their effect on miR-190, miR-196a, miR-221 and miR-222

  2020cites this paper
• Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs

  2017cites this paper
• Alteraciones epigenéticas en la progresión del cáncer cervicouterino

  2015cites this paper
• Combination of Ethanolic Extract of Citrus aurantifolia Peels with Doxorubicin Modulate Cell Cycle and Increase Apoptosis Induction on MCF-7 Cells

  2014cites this paper
• Drug Resistance and Molecular Cancer Therapy: Apoptosis Versus Autophagy

  2013cites this paper
• Autophagy, Apoptosis, Mitoptosis and Necrosis: Interdependence Between Those Pathways and Effects on Cancer

  2012cites this paper
• Stem cells in breast tumours: are they ready for the clinic?

  2012cites this paper
• Chemotherapy-Induced Weakness and Fatigue in Skeletal Muscle: The Role of Oxidative Stress

  2011cites this paper
• Quality of life and toxicity in breast cancer patients using adjuvant TAC (docetaxel, doxorubicin, cyclophosphamide), in comparison with FAC (doxorubicin, cyclophosphamide, 5-fluorouracil)

  2011cites this paper
• Drugs interfering with apoptosis in breast cancer.

  2011cites this paper
• Small Molecule Inhibitors of Bcl-2 Family Proteins for Pancreatic Cancer Therapy

  2011cites this paper
• Cutaneous Melanoma: A Test Field for Immunotherapy and a Medical Challenge

  2010cites this paper
• Targeting mitochondria for cancer therapy

  2010cites this paper
• Chemoresistance to melanoma

  2009cites this paper
• Quimiorresistencia del melanoma

  2009cites this paper
• Phase I study of apoptosis gene modulation with oblimersen within preoperative chemotherapy in patients with primary breast cancer.

  2009cites this paper